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Background
The challenges of daily antiretroviral therapy (ART) have
stimulated interest in alternative treatment schedules such
as short cyclical interruptions of ART in virologically sup-
pressed patients. Short interruptions are intended to avoid
rebound viremia and its negative consequences, while
addressing "pill-fatigue," cumulative long-term toxicities,
and the cost associated with daily therapy.
Methods
60 subjects, all on daily efavirenz/tenofovir/emtricitabine
(EFV/TDF/FTC) with CD4 count >200 and durable viral
suppression, were randomized to continue daily therapy
or change their weekly schedule to 5 consecutive days on
treatment (typically Monday-Friday) followed by 2 days
off treatment (Five-On, Two-Off, or "FOTO" schedule).
HIV-RNA (VL) was measured at weeks 4, 12, 24; in the
FOTO arm, VL was drawn at the end of the 2-day interrup-
tion. AE, adherence, and QoL data were also collected. The
primary endpoint was the proportion in each arm with
virologic suppression (VL <50) at week 24. The study was
powered to detect a 15% or greater difference in favor of
the daily arm over the FOTO arm. Rates of virologic sup-
pression in the two arms were compared using the Far-
rington-Manning test.
Summary of results
30 were enrolled on each arm. Baseline characteristics
were similar in the two arms (15% women; mean age 45
years; mean CD4 count 663). Fifty-three completed 24
weeks on study: 25 on FOTO and 28 on daily treatment.
All seven who stopped prior to week 24 had an HIV-RNA
<50 at the time of study discontinuation. There were six
blips (VL 50 – 500) in the FOTO arm and nine blips in the
daily arm through week 24. There was no virologic failure
(confirmed VL >400) through week 24. By intent-to-treat
analysis (drop out = failure), 83% (95% CI: 70–97) on
FOTO vs. 80% (95% CI: 66–94) on daily treatment had
an HIV-RNA <50 at week 24. By as-treated analysis, 100%
(95% CI: 88–100) on FOTO vs. 86% (95% CI: 73–99) on
daily treatment had a VL <50 at week 24. Week 24 sup-
pression rates were equivalent in the two groups (p <
0.005) by the Farrington-Manning test. There were three
reported neuropsychiatric AEs: two on FOTO and one on
daily; all were judged mild.
Conclusion
These data confirm the success of a Five-day On/Two-day
Off strategy for maintaining virologic suppression for at
least 24 weeks on EFV/TDF/FTC. Follow-up is ongoing to
further assess durability. This treatment strategy could sig-
nificantly reduce antiretroviral drug costs, which is espe-
cially important in resource-scarce areas.
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